Results 251 to 260 of about 749,373 (347)

Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells

Advanced Science, EarlyView.
This study demonstrates that tumor‐derived IL‐35 promotes pancreatic cancer fibrosis by indirectly activating pancreatic stellate cells through IGFBP2/IGF‐1R/PI3K‐Akt and Tsp‐1/TGF‐β pathways. IL‐35 blockade reduces stromal fibrosis, restores chemosensitivity, and synergizes with gemcitabine‐based regimens, highlighting IL‐35 as a promising therapeutic
Hui Li, Huizhi Sun, Jing Liu, Yan Wu, Lin Wei, Jianming Li, Yudong Yuan, Peng Xie, Chao Xu, Guolu Luo, Yuqi Guan, Yukuan Feng, Antao Chang, Jihui Hao, Chongbiao Huang   +14 more
wiley   +1 more source

Proteomics in pancreatic cancer. [PDF]

Biomark Res
Cai F, Gu Y, Ling Y, Yi G, Zang S, Su T, Liu Y, Li A, Wang D, Zhao W, Xie X, Li G, Dai L, Gong M, Yang H, Zhao Y, Zhang Y.   +16 more
europepmc   +1 more source

Marine natural products in the discovery and development of potential pancreatic cancer therapeutics

, 2019
Xiaojuan Wang, Mark T. Hamann
openalex   +2 more sources

Clinofibrate Disrupts the SNORA80B/YTHDC1‐Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC

Advanced Science, EarlyView.
This study uncovers a non‐canonical role of SNORA80B in ESCC, showing it mediates AR‐driven metabolic reprogramming via N⁶‐methyladenosine (m6A) methylation. By binding YTHDC1, SNORA80B stabilizes cholesterol‐metabolic enzyme mRNAs and promotes tumor progression. The FDA‐approved drug clinofibrate inhibits SNORA80B by disrupting cholesterol homeostasis,
Hongyu Yuan, Ge Ge, LiQiu Liu, Sijun Hu, Miaomiao Tian, Yongzhan Nie, Zitong Zhao, Yongmei Song   +7 more
wiley   +1 more source

Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

Advanced Science, EarlyView.
This study presents heparin‐derived nanoparticles (HP‐NPs) as a novel precision medicine platform that combines therapeutic and delivery functions. HP‐NPs target drug‐resistant glioblastoma stem cells, reprogramming them into a drug‐sensitive phenotype and significantly reducing tumor progression.
Vadim Le Joncour, Austin D. Evans, Camilla Karoliina Bergström, Vignesh Kumar Rangasami, Sumanta Samanta, Nithiyanandan Krishnan, Yuji Teramura, Bo Nilsson, Patricia Hedenqvist, Elin Manell, Jons Hilborn, Marianne‐Jensen Waern, Oommen P. Varghese, Pirjo Laakkonen, Oommen P. Oommen   +14 more
wiley   +1 more source

[Retracted] miR‑381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer. [PDF]

Int J Mol Med
Qiao G, Li J, Wang J, Wang Z, Bian W.
europepmc   +1 more source

Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer

Advanced Science, EarlyView.
Neoadjuvant gemcitabine plus nab‐paclitaxel (AG) reprograms pancreatic ductal adenocarcinoma by shifting malignant cells toward a classical phenotype and remodeling the tumor microenvironment. Despite enhancing cytotoxic NKT cells, AG activates tumor‐associated mast cells (TAMCs) and inflammatory CAFs through MIF signaling.
Libo Wang, Guangcong Shen, Guanpeng Xie, Zekun Li, Xiaoqing Ma, Mengyu Li, Ziyun Liu, Yadi Wang, Zongjing Lv, Qingxiao Fang, Huihui Sun, Ningning Zhao, Chao Yang, Tianxing Zhou, Yongjie Xie, Jun Yu, Jihui Hao   +16 more
wiley   +1 more source

Biochemical Pseudoprogression in Pancreatic Cancer During Chemotherapy: A Case Report. [PDF]

Cureus
Mohamed A, Dao KT, Kim S.
europepmc   +1 more source

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)

, 2019
Federico Innocenti, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, Ace J. Hatch, Herbert I. Hurwitz, Andrew B. Nixon, Yoichi Furukawa, Michiaki Kubo, Daniel J. Crona, Hedy L. Kindler, Howard L. McLeod, Mark J. Ratain, Kouros Owzar   +16 more
openalex   +2 more sources

TMEM131‐Mediated Soluble TRAIL Triggered Type II Alveolar Epithelial Cell Senescence in Radiation‐Induced Lung Injury

Advanced Science, EarlyView.
TMEM131 recruits the COPII complex to accelerate TRAIL transportation from endoplasmic reticulum to Golgi apparatus, and promotes soluble TRAIL secretion. TRAIL inhibits mitophagy and induces senescence through DR5 receptor in type II alveolar epithelial cells, ultimately driving radiation‐induced lung injury (RILI) progression.
Linzhi Han, Chunsheng Wang, Xiuli Guo, Yuan Luo, Jianguo Zhang, Fajian He, Zihang Zeng, Jiang Luo, Wen Ouyang, Yan Gong, Conghua Xie   +10 more
wiley   +1 more source